125742 45 S252 M5 c4591001 S roadmap

Pfizer Documents (PHMPT/FDA)

Pfizer Bla Submission

Pfizer 12 15 Documents

4

Document text

C4591001: R oadmap  for Event Selection and SDTM Dataset Updates  for Reactogenicity  
 
Background:   As discussed with the Agency on 08 April 2021, any events reported in the general 
adverse event data (AE domain ) which meet criteria for reactogenicity  have been added to the FACE 
and VS domains and used to update the summary records in the CE domain , as described below. 
 
 
   
Add a flag in SUPPDM : QNAM=REACTOFL, QLABEL=Reactogenicity Population Fl ag  
For vaccinated subjects (DM.RFXSTDTC non- missing):  
a. Assign QVAL  as “N” if “NO - REACTOGENICITY E -DIARY NOT COLLECTED FOR THIS SUBJECT ” was 
selected in REACTOGENICITY DIARY  CRF 
b. Otherwise assigned as “Y”  
 
Select from AE data: If AECAT = “ ADVERSE EVENT ” and AEREL = 
‘RELATED’ and AEDECOD in (preferred term list corresponding to 
pre-defined reactogenicity symptoms – see Table 1 below) and 
occurs within 7 days of Vax 1 or Vax 2).   
 
If meet both criteria, then a dd flag in SUPPAE  to identify that these 
meet reactogenicity criteria ( QVAL = “Y” where QNAM = “ REACCRIT ”) 
 Select subjects from SUPPDM  
with QVAL = “Y” where  
 QNAM  = REACTOF L 
 
 Reactogenicity Symptom 
(CETERM)  PT (AEDECOD)  
PAIN AT INJECTION SITE  Injection site pain  
Vaccination site pain  
REDNESS  Injection site erythema  
Vaccination site erythema  
SWELLING  Injection site swelling  
Vaccination site swelling  
FEVER  Pyrexia  
Body temperature increased  
VOMITING  Vomiting  
DIARRHEA  Diarrhoea  
HEADACHE  Headache  
FATIGUE  Fatigue  
CHILLS  Chills  
NEW OR WORSENED 
MUSCLE PAIN  Myalgia  
NEW OR WORSENED JOINT 
PAIN  Arthralgia  
 Y Start  
Table 1  
090177e19939f709\Final\Final On: 31-Jan-2022 15:29 (GMT)
FDA-CBER-2022-5812-0492782
 
 
   
AETOXGR  Severity  
1 MILD  
2 MODERATE  
3 SEVERE  
4 POTENTIALLY LIFE THREATENING  Add records to FACE for investigator’s assessment  from 
AE form : 
a. For each day AE overlaps with diary period, 
insert a pair of records for FATESTCD = 
‘OCCUR’ (set to ‘Y’) and FATEST CD = ‘SEV’ 
(from AETOXGR, converted to severity  
according to Table 2 below) for that date 
(FADTC) .   
b. Assign FAOBJ based on the symptom corresponding to AEDECOD (CETERM from 
Table 1) . 
c. FACAT = “ REACTOGENICITY – ADVERSE 
EVENT ”.   
d. FASCAT (“SYSTEMIC” or “ADMINISTRATION 
SITE”) assigned based on FAOBJ.  
e. FASPID is assigned the value of AESPID from 
source AE record.  
f. FAEVAL = ‘INVESTIGATOR’. 
 
 
 
 
 
 
 
 For general AE  records identified 
as meeting r eactogenicity criteria  
(SUPPAE. QNAM .REACCRIT = “Y”):  
 
Fever?  Y N 
Add records to VS for investigator’s assessment  from 
AE form : 
a. For each day AE overlaps with diary period, 
insert a record  for VSTESTCD = ‘TEMP’: 
VSORRES is null, VSSTRESC = “FEVER” for that date (VSDTC).  
b. VSDRVDL is set to “Y”.     
c. VSCAT = “ REACTOGENICITY – ADVERSE 
EVENT ”.   
d. VSSCAT = “SYSTEMIC” . 
e. VSSPID is assigned the value of AESPID from 
source AE record.  
f. VSEVAL = ‘INVESTIGATOR’. 
 
 
 
 
 
 
 
 
Table 2  
090177e19939f709\Final\Final On: 31-Jan-2022 15:29 (GMT)
FDA-CBER-2022-5812-0492783
 
   
a. Flag in SUPPCE that event was modified based on AE data (QNAM = 
‘AE_MOD’)  
b. Create  record in SUPPCE with QNAM = ‘CEDIFFRS’/QLABEL = ‘Reason 
Investigator Changed Assessment’.   
c. Assign SUPPCE.CEEVAL = “INVESTIGATOR”. 
 
 
 
 
 
 
 
 When general AE data affects the  
corresponding summary event 
record in CE   CE/SUPPCE  updates  
 
a. Re-derive CESTDTC by taking the earliest of 
AESTDTC and original CESTDTC . 
b. Re-derive CEENDTC by taking the latest of 
AEENDTC and original CEENDTC.    
c. For any date changes, write original date  to 
SUPPCE.CESTDTC1 and/or CEENDTC1.  
d. CESTDY/CEENDY/CEDUR are updated based on 
any changes to CESTDTC/CEENDTC. 
e. Re-derive CESEV by taking the maximum severity 
from AETOXGR (mapped to severity according to 
Table 2) or original CESEV.  If AE severity is worse than original CESEV, then write out original value 
to SUPPCE where QNAM = CESEV1.  Note: 
Severity is not assigned for Fever events.  
f. If stop date is after diary period, then assign 
CEENRTPT = “ ONGOING ” and CEENTPT = “ DAY 7 ”. 
 
 
 
 
 
 
 
 a. Assign CEOCCUR= “Y” and set 
CESTAT/CEREASND/CEDRVFL to null.  
b. Populate CESTDTC/CEENDTC with 
AESTDTC/AEENDTC.  
c. Derive CESTDY/CEENDY and CEDUR.  
d. Set CESEV based on AETOXGR, mapped to severity values in Table 2.  
e. If stop date is after diary period, then assign CEENRTPT = “ ONGOING ” and 
CEENTPT = “ DAY 7 ”. 
 
 
 
 
 
 
 
 Originally CEOCCUR was “Y” 
 Originally CEOCCUR was not “Y” 
 
090177e19939f709\Final\Final On: 31-Jan-2022 15:29 (GMT)
FDA-CBER-2022-5812-0492784
 
 
Add or update records to AE dataset  where  AECAT = 
‘REACTOGENICITY’ .   
a. Calculate AEDUR based on time occurring after diary 
period  using updated CEENDTC . 
b. Derive AE ELTM.  
c. AESEV can be populated using AETOXGR, mapped to 
severity from Table 2.  
 
Update RELREC  to link any newly added records.  
Link source general  AE records to updated CE records.   
 
End 
 Identify events from updated CE 
which went past the diary period 
(CEENRTPT = “ONGOING” ) 
090177e19939f709\Final\Final On: 31-Jan-2022 15:29 (GMT)
FDA-CBER-2022-5812-0492785